Daily Digest
Piramal Pharma Acquires Controlling Stake in Yapan Bio
Published Wednesday, August 19, 2026 · Updated August 19
Narrative Spectrum
- Single-Source Coverage — 1 source
What We Know — Key Points
Key points are extracted by an AI model and may contain errors or omissions. Always check the original sources.- Piramal Pharma Ltd. acquired an incremental 40.67% stake in Yapan Bio Private Limited for ₹76 crore, or $7.95M USD.
What Is Claimed — Perspectives
Single-Source Coverage
- The Hindu
The article emphasizes how this acquisition enhances Piramal Pharma's ability to offer integrated large molecule CDMO services and supports its ADCelerate™ platform, ultimately aiming to meet global demand for complex biologics and improve patient access to therapies.
- Read original →· Aug 19
AI-Generated Content
- This topic was generated by an AI system.
- Key points, perspectives, bias labels, and categorisation may contain errors.
- This is not journalism. Do not rely on this content for critical decisions.
- Read our full AI disclaimer for details.